Ginger efficacy in patients uncontrolled on standard moderate asthma treatment

Ginger efficacy in patients uncontrolled on standard moderate asthma treatment: a randomized, double-blind, placebo-controlled, cross-over study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201010194970N1

Enrollment

Registered

2010-12-12

Start date

2010-11-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma. Moderate asthma

Interventions

Intervention 1: Type of intervention: Ginger powder, oral 250 mg capsule, three times daily for 10 weeks. Intervention 2: Control group: Placebo.

Treatment - Drugs

Placebo

Type of intervention: Ginger powder, oral 250 mg capsule, three times daily for 10 weeks

Control group: Placebo

Eligibility

Sex/Gender

All

Age

16 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 40 consenting non-smoking patients aged between 16 and 70 years with a documented positive bronchodilator reversibility test with = 15% improvement in FEV1 from 15 to 30 minutes after inhalation of at least 200 µg of salbutamol are enrolled in the 10-week, randomized controlled cross over study. Exclusion criteria for the study are: emergency treatment for an asthma exacerbation within one month, COPD, upper airway infections in the last three weeks, hospitalization for asthma in the three months previous to enrolment, treatment with antihistamines, anticholinergics, theophyline and chromones, oral corticosteroids and ß2 agonists, presence of autoimmune, cardiac, hepatic or renal disorders, malabsorption, drug-addiction, pregnancy and lactation.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Spirometric tests. Timepoint: Weeks 1, 3, 5, 6, 8, 10. Method of measurement: Spirometry apparatus.;Immunologic tests. Timepoint: Weeks 1, 3, 5, 6, 8, 10. Method of measurement: laboratorial evaluation of IgE and sputum eosinophil.;Condition of asthma control. Timepoint: Weeks 1, 3, 5, 6, 8, 10. Method of measurement: Clinical memoir, physical examination, completion of asthma control questionnaires.	—

Measure

Time frame

Spirometric tests. Timepoint: Weeks 1, 3, 5, 6, 8, 10. Method of measurement: Spirometry apparatus.;Immunologic tests. Timepoint: Weeks 1, 3, 5, 6, 8, 10. Method of measurement: laboratorial evaluation of IgE and sputum eosinophil.;Condition of asthma control. Timepoint: Weeks 1, 3, 5, 6, 8, 10. Method of measurement: Clinical memoir, physical examination, completion of asthma control questionnaires.

—

Secondary

Measure	Time frame
Side effect of drugs. Timepoint: weeks 1, 3, 5, 6, 8, 10. Method of measurement: Clinical memoir, Physical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Nazanin Mansouri

School of Medicine, Mazandaran University of Medical Sciences

mansourinazanin@yahoo.com+98 15 1226 1700

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026